Castle Biosciences (CSTL) Non-Current Deferred Tax Liability (2020 - 2026)

Castle Biosciences has disclosed Non-Current Deferred Tax Liability across 7 years of filings, most recently posting $2.3 million for Q2 2026.

• In Q2 2026, Non-Current Deferred Tax Liability fell 25.72% year-over-year to $2.3 million; the TTM figure through Jun 2026 stood at $2.3 million (down 25.72% YoY), while the FY2025 annual figure was $2.3 million, down 90.39% from the prior year.
• Non-Current Deferred Tax Liability came in at $2.3 million for Q2 2026 at Castle Biosciences, roughly flat from $2.3 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $27.1 million in Q4 2022 to a low of $206000.0 in Q1 2024.
• Average Non-Current Deferred Tax Liability over 5 years is $5.8 million, with a median of $2.3 million recorded in 2026.
• Year-over-year, Non-Current Deferred Tax Liability surged 856.92% in 2024 and tumbled 90.39% in 2025.
• Over 5 years, Non-Current Deferred Tax Liability stood at $27.1 million in 2022, then declined by 9.0% to $24.7 million in 2023, then dropped by 1.58% to $24.3 million in 2024, then plunged by 90.39% to $2.3 million in 2025, then slipped by 0.56% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $2.3 million in Q2 2026, $2.3 million in Q1 2026, and $2.3 million in Q4 2025.